MarketPeel
Insider Trading Intelligence
Pricing
…
NB

Namandje Bumpus

RXRX
DIRECTOR · RECURSION PHARMACEUTICALS, INC. · CIK 0002060594
FILING MIX · LIFETIME71%/29%
BUYS
5
SELLS
2
TOTAL VALUE
$28.1K
COMPANIES
1
ACTIVE SINCE
Mar 2025
HOLDINGS NOW
127,632
AVG SELL PX
$3.37
TRADE KIND
SHOWING 7 / 7
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
No backtest data available for Namandje Bumpus. Backtests are computed for purchase (P) and sale (S) transactions with resolvable price history.
Holdings over time
RXRX · 127,632 shares · as of Jun 18, 2026
032,89965,79898,696131,5952026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2025
2025
2025
2025
2026
2026
FLOW · 5 buys / 2 sellsCOVERAGE · 6 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,963$3.18$12.6K127,632Jun 18, 2026Jun 22, 2026 ↗View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
88,424——131,595Jun 17, 2026Jun 22, 2026 ↗View →
RXRX
RECURSION PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
4,386$3.54$15.5K43,171Jun 3, 2026Jun 4, 2026 ↗View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
11,008——47,557Jun 18, 2025Jun 23, 2025 ↗View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
22,016——22,016Jun 18, 2025Jun 23, 2025 ↗View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
36,549——36,549Mar 17, 2025Mar 19, 2025 ↗View →
RXRX
RECURSION PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
73,099——73,099Mar 17, 2025Mar 19, 2025 ↗View →
Other insiders · RXRX
Loading peer insiders…
About this filer
CIK 0002060594
ROLE
Director
PRIMARY
RXRX
COMPANIES
1
ACTIVE SINCE
Mar 2025
MARKETPEEL · /INSIDER/0002060594DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback